Literature DB >> 2635285

Pericardial fibrosis following busulfan treatment.

W Terpstra, C E de Maat.   

Abstract

A case is reported of pericardial fibrosis after busulfan treatment in a man with chronic myeloid leukaemia. In the absence of any other explanation, we assume that busulfan may have been the cause of pericardial fibrosis in this patient. Other drugs causing pericardial fibrosis are discussed.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2635285

Source DB:  PubMed          Journal:  Neth J Med        ISSN: 0300-2977            Impact factor:   1.422


  5 in total

Review 1.  Cancer Treatment-Associated Pericardial Disease: Epidemiology, Clinical Presentation, Diagnosis, and Management.

Authors:  Chandra K Ala; Allan L Klein; Javid J Moslehi
Journal:  Curr Cardiol Rep       Date:  2019-11-25       Impact factor: 2.931

2.  Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging.

Authors:  Juan Carlos Plana; Maurizio Galderisi; Ana Barac; Michael S Ewer; Bonnie Ky; Marielle Scherrer-Crosbie; Javier Ganame; Igal A Sebag; Deborah A Agler; Luigi P Badano; Jose Banchs; Daniela Cardinale; Joseph Carver; Manuel Cerqueira; Jeanne M DeCara; Thor Edvardsen; Scott D Flamm; Thomas Force; Brian P Griffin; Guy Jerusalem; Jennifer E Liu; Andreia Magalhães; Thomas Marwick; Liza Y Sanchez; Rosa Sicari; Hector R Villarraga; Patrizio Lancellotti
Journal:  Eur Heart J Cardiovasc Imaging       Date:  2014-10       Impact factor: 6.875

Review 3.  Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention.

Authors:  V B Pai; M C Nahata
Journal:  Drug Saf       Date:  2000-04       Impact factor: 5.606

Review 4.  [Cardiac disease in patients with tumors and tumor therapy].

Authors:  U C Hoppe
Journal:  Internist (Berl)       Date:  2007-03       Impact factor: 0.743

5.  Busulphan-cyclophosphamide cause endothelial injury, remodeling of resistance arteries and enhanced expression of endothelial nitric oxide synthase.

Authors:  Sulaiman Al-Hashmi; Piet J M Boels; Fahad Zadjali; Behnam Sadeghi; Johan Sällström; Kjell Hultenby; Zuzana Hassan; Anders Arner; Moustapha Hassan
Journal:  PLoS One       Date:  2012-01-27       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.